buy

Alnylam Pharmace. buy Needham & Company LLC

Alnylam Pharmace.

Start price

€137.00

/ 50%

Target price

15.02.25

Performance (%)

Price

Summary

This prediction is currently active. With a performance of , the BUY prediction by Needham___Company_LL is trending in the wrong direction. This prediction currently runs until 15.02.25. The prediction end date can be changed by Needham___Company_LL at any time. Needham___Company_LL has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

Feedback

Performance without dividends (%)

Name	1w	1m
Alnylam Pharmace.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by Needham___Company_LL for this prediction

In the thread Alnylam Pharmace. diskutieren

Prediction Buy

Perf. (%)

Target price 185.660

Change

Ends at

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $200.00 price target on the stock.

Ratings data for ALNY provided by MarketBeat

Needham & Company LLC